CytomX Therapeutics appoints Charles Fuchs to board of directors

The clinical-stage oncology company said Fuchs brings more than three decades of cancer drug development experience as it advances Varseta-M and its broader PROBODY pipeline.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.